Last update 19 Sep 2024

Pregnancy, Tubal

Last update 19 Sep 2024

Basic Info

Synonyms

ECTOPIC PREGNANCY TUBAL, FALLOPIAN TUBE PREGNANCY, Fallopian pregnancy

+ [33]

Introduction

The most common (>96%) type of ectopic pregnancy in which the extrauterine EMBRYO IMPLANTATION occurs in the FALLOPIAN TUBE, usually in the ampullary region where FERTILIZATION takes place.

Clinical Trials associated with Pregnancy, Tubal

NCT06300333 / Not yet recruitingNot ApplicableIIT

Effectiveness and Safety of a New Methotrexate Regimen in Treatment of Undisturbed Tubal Ectopic Pregnancy : A Pilot Prospective Study

Evaluate the efficacy and safety of the use of low dose regimen of methotrexate in treatment of tubal undisturbed tubal ectopic pregnancy

Start Date01 Mar 2024

Sponsor / Collaborator

Assiut University

NCT05498558 / Not yet recruitingNot ApplicableIIT

The Selection of Pregnancy for Patients After Tubal Ectopic Pregnancy Treatment In Pudong New Area

The incidence of re-ectopic pregnancy in patients with tubal ectopic pregnancy increases significantly, which may be related to the condition of the fallopian tubes, such as tubal inflammation, tubal obstruction and other high-risk factors that may lead to tubal ectopic pregnancy; it is also associated with the treatment of the previous tubal ectopic pregnancy. Compared with salpingectomy, the treatment of preserving the fallopian tubes increased the incidence of re-ectopic pregnancy while increasing the pregnancy rate of the patient. For tubal-preserving patients, the most common option currently used is to recommend that monitoring ovulation during each menstrual cycle if they choose to conceive naturally rather than IVF. If ovulation occures on the healthy side of the ovary, it may be considered to try to conceive; Otherwise, contraception is recommended. However, there are uncertainties about this option. Based on this, we intend to conduct a multicenter clinical trial to verify the effectiveness of the ovulation preparation regimen on the healthy side of ovary.

Start Date01 Jan 2023

Sponsor / Collaborator

Shanghai Pudong Hospital

NCT06426979 / CompletedNot ApplicableIIT

Sequential Letrozole and Methotrexate Therapy Safely Improved the Outcomes of Medical Treatment of Tubal Ectopic Pregnancy

Ectopic pregnancy (EP) is a common condition involving the implantation of fertilized ovum outside the uterine cavity, accounting for 1-2% of all pregnancies. Tubal EP (TEP) is the most common and poses a significant risk to maternal life. Early diagnosis and medical treatment, such as methotrexate (MTX) and the Fallopian tube (FT), have been studied. However, the efficacy of single-dose methotrexate (SD-MTX) is questionable, and the efficacy of two-dose versus SD-MTX for medical management of EP is being evaluated. High estrogens/progesterone ratios can disrupt embryonic motility and lead to TEP.

Start Date01 Jan 2023

Sponsor / Collaborator

Zagazig University

100 Clinical Results associated with Pregnancy, Tubal

100 Translational Medicine associated with Pregnancy, Tubal

0 Patents (Medical) associated with Pregnancy, Tubal

2,083

Literatures (Medical) associated with Pregnancy, Tubal

01 Mar 2024·European journal of obstetrics & gynecology and reproductive biology: X

Methotrexate as the first-line treatment of unruptured tubular ectopic pregnancies with high initial human chorionic gonadotropin levels: A retrospective cohort.

Article

Author: Fatemeh Keikha ; Shireen Shams Ardekani ; Mohammadamin Parsaei ; Nikan Zargarzadeh ; Alireza Hadizadeh ; Azadeh Tarafdari

Objectives:

To evaluate the effectiveness of the first-line medical management with Methotrexate (MTX) in the treatment of patients with stable tubal Ectopic Pregnancies (EPs) and varying ranges of Beta-Human Chorionic Gonadotropin (β-HCG) levels.

Materials and methods:

In this retrospective cohort study, we reviewed the medical records of a total of 184 patients with the diagnosis of tubal EP, who received MTX as their first-line treatment. Patients with a baseline β-HCG< 4800 mIU/mL received single-dose MTX (n = 136) and those with an initial β-HCG≥ 4800 mIU/mL underwent the double-dose MTX regimen (n = 48). The treatment success was determined by evaluating the reported weekly β-HCG levels of the patients.

Results:

Baseline β-HCG and mass size in the single-dose group were 1895.1 ± 1463.4 mIU/mL and 2.2 ± 1.1 cm, respectively, compared to 17,867.6 ± 31,870.5 mIU/mL and 2.3 ± 1.1 cm in the double-dose group. Treatment duration was 30.6 ± 16.9 days for single dose and 41.0 ± 27.0 days for double dose, with additional MTX in 27.2% and 12.5% in respective groups. Single dose achieved a 92.6% success rate, and double dose, 81.3%, without serious adverse effects. No significant effects were seen for either baseline β-HCG and mass size on the treatment success rates of both groups (p-value>0.05). However, the presence of Fetal Heart Rate (FHR) was associated with poorer responses only in the single-dose group (p-value=0.034).

Conclusions:

Medical management with MTX shows promise as a first-line treatment for tubal EPs with β-HCG> 2000, suggesting a potential reassessment of existing guidelines in light of this emerging evidence. However, further research seems crucial in this field.

12 Feb 2024·European journal of obstetrics, gynecology, and reproductive biology

Unusual presentation of late-stage ectopic tubal pregnancy (19 weeks' gestation): Case report and literature review.

Review

Author: Danijel Bursać ; Matilda Zadro ; Suzana Haramina ; Diana Culej Bošnjak ; Neven Tučkar ; Krunoslav Kuna

Ectopic pregnancy is a medical condition in which a fertilized egg takes an unexpected detour away from the uterine cavity and the fallopian tube becomes a popular host, with the ampulla being the prime location. However, it can occur in other areas such as cervix, ovaries, or abdomen. The most common risk factors are pelvic inflammatory disease, previous pelvic or abdominal surgery, abnormal anatomy of genital organs, endometriosis, previous ectopic pregnancies, assisted reproductive technologies, endocrine disorders, and even the subtle influence of low-dose progestins from contraceptives. We will present a rare case of unrecognized late-stage tubal ectopic pregnancy. The following case report is of a 25-year-old Caucasian female patient (G2, P0) who presented to the emergency department with a 24-hour abdominal pain syndrome. The patient did not have a gynecological examination for this reason. During the examination, taking into account the clinical and ultrasound findings, a suspicion of pregnancy in a bicornuate uterus was raised, and an MRI of the pelvis was performed. MRI showed ectopic pregnancy in the left fallopian tube with a properly developed fetus that corresponded to a gestation of 19 weeks. An emergency laparotomy was performed and the left fallopian tube with the fetus was removed. The early and late course of recovery went smoothly. The patient was discharged after adequate clinical development.

30 Jan 2024·Heliyon

Transvaginal natural orifice endoscopic surgery for tubal ectopic pregnancy: A more suitable surgical approach for enhanced recovery after surgery.

Article

Author: Ying Liu ; Xin Li ; Tianjiao Liu ; Aijie Xie ; Xian Wu ; Yujian Jia ; Xiaoyan Liao ; Wei Cheng ; Hui Wang ; Fangyuan Zhong ; Lijuan Xu ; Juan Huang ; Siqin Xiu ; Zhongzhi Li ; Yalan Li ; Xue Xiao ; Yonghong Lin ; Xiaoqin Gan

Objective:

We aimed to determine the safety of Vaginal natural orifice transluminal endoscopic surgery (vNOTES) in terms of the Enhanced Recovery after Surgery (ERAS) concept for tubal pregnancy surgery and provide a detailed process of vNOTES for tubal pregnancy surgery, including experience and key points for surgeons performing this procedure.

Methods:

The Longitudinal Vaginal Natural Orifice Transluminal Endoscopic Surgery Study (LovNOTESS), which was conducted in Chengdu, China. A total of 219 patients who underwent tubal ectopic pregnancy surgery between September 2021 and March 2022. The patients underwent salpingectomy or salpingostomy using transumbilical laparoendoscopic single-site surgery (LESS) or vNOTES, according to their preferences. This study prospectively collected perioperative and one-year follow-up data on tubal pregnancy outcomes after vNOTES and compared them with those after LESS.

Results:

The vNOTES group showed a shorter surgical duration, hospitalization duration, and postoperative exhaust time and a lower analgesic medication usage rate, but it showed a higher surgical conversion rate. The vNOTES approach reduced the postoperative exhaust time by approximately 9 h (95% confidence interval [CI]: -11.93, -5.57 h, p < .001) and the risk of postoperative analgesic drug use by 77% (odds ratio, 0.23; 95% CI: 0.10, 0.61, p = .023).

Conclusion:

vNOTES can shorten the exhaust time and duration of hospitalization, reduce postoperative pain, and avoid surface surgical scars in tubal pregnancy surgeries, consistent with the ERAS concept. However, more comprehensive preoperative evaluation of patients who choose vNOTES is required to reduce the occurrence of intraoperative conversion.Trial registration: ChiCTR2100053483.

News (Medical) associated with Pregnancy, Tubal

03 Dec 2022

·www.prnewswire.com

Intrauterine Contraceptive Devices (IUD) market 2023-2027: 5-Year (2017-2021) Historic Industry Size & Analysis of 15 Vendors and 7 Countries - Technavio

NEW YORK, Dec. 3, 2022 /PRNewswire/ -- The intrauterine contraceptive devices (IUD) market size is forecast to grow by USD 965.49 million from 2022 to 2027, with an accelerated CAGR of 3.98%, according to the recent market study by Technavio. This report also offers a 5-year historical (2017-2021) data projection of market size, segmentation, and region. Discover some insights on market size before buying the full report. Request a free sample report. Continue Reading Technavio has announced its latest market research report titled Global Intrauterine Contraceptive Devices (IUD) Market 2023-2027 Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak. The Bargaining Power of Buyers & Suppliers and the Threat of New Entrants, Rivalry, and Substitutes have also been analyzed and rated between LOW-HIGH to provide a holistic view of market favorability. Find Technavio's Exclusive Analysis of Price Sensitivity, Adoption Lifecycle, Customer Purchase Basket, Adoption Rates, and Purchase Criteria One of the core components of the customer landscape is price sensitivity, an analysis of which will help companies refine marketing strategies to gain a competitive advantage. Another key aspect is price sensitivity drivers ( purchases are undifferentiated, the purchase is a key cost to buyers, and quality is not important), which range between LOW and HIGH. Furthermore, market adoption rates for all regions have been covered. The intrauterine contraceptive devices (IUD) market report also offers information on the criticality of inputs, R&D, CAPEX, technology, and products of 15 vendors listed Below – Bayer AG DKT International Durbin PLC EurimPharm Arzneimittel GmbH EUROGINE SL Gima Spa HLL Lifecare Ltd. Krishco Medical Products Pvt. Ltd. Laboratoire HRA Pharma SAS Melbea Innovations Ltd. Meril Life Sciences Pvt. Ltd. Ocon Medical Ltd. Pregna International Ltd Prosan International BV SMB Corp. of India Download a sample report Chart & Data Table on 5-Year Historic (2017-2021) Market Size, Comparative Analysis of Segments, and Y-O-Y Growth of intrauterine contraceptive devices (IUD) market The market is segmented by type (hormonal intrauterine device and copper intrauterine device) and end-user (hospitals, gynecology clinics, and others). Based on type, the hormonal intrauterine device segment became the market's largest segment in 2022. Hormonal intrauterine devices decrease the risk of pelvic inflammatory disease (PID) and tubal pregnancies and help in treating symptoms such as polycystic ovary syndrome (PCOS) and endometriosis. Hormonal intrauterine devices are more effective in preventing pregnancies when compared with other contraception devices. They are superior to copper intrauterine devices and pose fewer complications and risks. To procure the data - Buy report! The increasing number of unplanned pregnancies and unwanted abortions is the key factor driving the global intrauterine contraceptive devices (IUD) market growth. The growing number of unplanned pregnancies is expected to contribute to the growth of the global intrauterine contraceptive devices (IUD) market. Unintended pregnancies are one of the most pressing public health problems and a significant issue in global reproductive healthcare, imposing a substantial socioeconomic burden on society and individuals. According to WHO, in developing countries, almost half of the pregnancies among adolescent girls aged 15-19 years are unplanned. The adoption of contraceptive methods can lower the rate of such pregnancies. Chart & Data Table on Historical Market Size (2017-2021, Historic Industry Size & Analysis of 15 Vendors and 7 Countries The market is segmented by region (North America, Europe, APAC, and the Rest of World). An analysis of key leading countries has been included. North America, will account for 33% of the market's growth during the forecast period. The US leads the intrauterine contraceptive devices (IUD) market in North America. The presence of local market players, supportive government initiatives, high awareness, and technological innovations such as postpartum and reusable IUDs drive market growth in the US. According to the Centers for Disease Control and Prevention (CDC), almost half of pregnancies in the US are unintended. Hence, the country experiences a high adoption of intrauterine devices among women. For Insights on the market dynamics & segmentations, VIEW A PDF SAMPLE ! Related Reports - Emergency Contraceptive Pills Market by Distribution Channel and Geography – Forecast and Analysis 2021-2025: The emergency contraceptive pills market size is forecast to grow up to USD 75.56 million at a CAGR of 1.64% during 2020-2025. Female Contraceptive Market by Distribution Channel, Product, and Geography – Forecast and Analysis 2023-2027: The female contraceptive market is forecast to grow at a CAGR of 5.32% between 2022 and 2027. The size of the market is forecast to increase by USD 5,.22 million. Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Table of Contents: 1 Executive Summary 1.1 Market Overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Type Exhibit 06: Executive Summary – Chart on Market Segmentation by End-user Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global intrauterine contraceptive devices (IUD) market 2017 - 2021 Exhibit 18: Historic Market Size – Data Table on Global intrauterine contraceptive devices (IUD) market 2017 - 2021 ($ million) 4.2 Type Segment Analysis 2017 - 2021 Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ million) 4.3 End-User Segment Analysis 2017 - 2021 Exhibit 20: Historic Market Size – End-User Segment 2017 - 2021 ($ million) 4.4 Geography Segment Analysis 2017 - 2021 Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million) 4.5 Country Segment Analysis 2017 - 2021 Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 5.5 Threat of substitutes Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Type 6.1 Market segments Exhibit 30: Chart on Type - Market share 2022-2027 (%) Exhibit 31: Data Table on Type - Market share 2022-2027 (%) 6.2 Comparison by Type Exhibit 32: Chart on Comparison by Type Exhibit 33: Data Table on Comparison by Type 6.3 Hormonal intrauterine device - Market size and forecast 2022-2027 Exhibit 34: Chart on Hormonal intrauterine device - Market size and forecast 2022-2027 ($ million) Exhibit 35: Data Table on Hormonal intrauterine device - Market size and forecast 2022-2027 ($ million) Exhibit 36: Chart on Hormonal intrauterine device - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Hormonal intrauterine device - Year-over-year growth 2022-2027 (%) 6.4 Copper intrauterine device - Market size and forecast 2022-2027 Exhibit 38: Chart on Copper intrauterine device - Market size and forecast 2022-2027 ($ million) Exhibit 39: Data Table on Copper intrauterine device - Market size and forecast 2022-2027 ($ million) Exhibit 40: Chart on Copper intrauterine device - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Copper intrauterine device - Year-over-year growth 2022-2027 (%) 6.5 Market opportunity by Type Exhibit 42: Market opportunity by Type ($ million) 7 Market Segmentation by End-user 7.1 Market segments Exhibit 43: Chart on End-user - Market share 2022-2027 (%) Exhibit 44: Data Table on End-user - Market share 2022-2027 (%) 7.2 Comparison by End-user Exhibit 45: Chart on Comparison by End-user Exhibit 46: Data Table on Comparison by End-user 7.3 Hospitals - Market size and forecast 2022-2027 Exhibit 47: Chart on Hospitals - Market size and forecast 2022-2027 ($ million) Exhibit 48: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million) Exhibit 49: Chart on Hospitals - Year-over-year growth 2022-2027 (%) Exhibit 50: Data Table on Hospitals - Year-over-year growth 2022-2027 (%) 7.4 Gynecology clinics - Market size and forecast 2022-2027 Exhibit 51: Chart on Gynecology clinics - Market size and forecast 2022-2027 ($ million) Exhibit 52: Data Table on Gynecology clinics - Market size and forecast 2022-2027 ($ million) Exhibit 53: Chart on Gynecology clinics - Year-over-year growth 2022-2027 (%) Exhibit 54: Data Table on Gynecology clinics - Year-over-year growth 2022-2027 (%) 7.5 Others - Market size and forecast 2022-2027 Exhibit 55: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibit 56: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibit 57: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibit 58: Data Table on Others - Year-over-year growth 2022-2027 (%) 7.6 Market opportunity by End-user Exhibit 59: Market opportunity by End-user ($ million) 8 Customer Landscape 8.1 Customer landscape overview Exhibit 60: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape 9.1 Geographic segmentation Exhibit 61: Chart on Market share by geography 2022-2027 (%) Exhibit 62: Data Table on Market share by geography 2022-2027 (%) 9.2 Geographic comparison Exhibit 63: Chart on Geographic comparison Exhibit 64: Data Table on Geographic comparison 9.3 North America - Market size and forecast 2022-2027 Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.4 Europe - Market size and forecast 2022-2027 Exhibit 69: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 70: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 71: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 72: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.5 APAC - Market size and forecast 2022-2027 Exhibit 73: Chart on APAC - Market size and forecast 2022-2027 ($ million) Exhibit 74: Data Table on APAC - Market size and forecast 2022-2027 ($ million) Exhibit 75: Chart on APAC - Year-over-year growth 2022-2027 (%) Exhibit 76: Data Table on APAC - Year-over-year growth 2022-2027 (%) 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 Exhibit 77: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 78: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 79: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibit 80: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 9.7 US - Market size and forecast 2022-2027 Exhibit 81: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibit 82: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibit 83: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 84: Data Table on US - Year-over-year growth 2022-2027 (%) 9.8 Germany - Market size and forecast 2022-2027 Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%) 9.9 China - Market size and forecast 2022-2027 Exhibit 89: Chart on China - Market size and forecast 2022-2027 ($ million) Exhibit 90: Data Table on China - Market size and forecast 2022-2027 ($ million) Exhibit 91: Chart on China - Year-over-year growth 2022-2027 (%) 105 Exhibit 92: Data Table on China - Year-over-year growth 2022-2027 (%) 9.10 France - Market size and forecast 2022-2027 Exhibit 93: Chart on France - Market size and forecast 2022-2027 ($ million) Exhibit 94: Data Table on France - Market size and forecast 2022-2027 ($ million) Exhibit 95: Chart on France - Year-over-year growth 2022-2027 (%) Exhibit 96: Data Table on France - Year-over-year growth 2022-2027 (%) 9.11 Japan - Market size and forecast 2022-2027 Exhibit 97: Chart on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 98: Data Table on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 99: Chart on Japan - Year-over-year growth 2022-2027 (%) Exhibit 100: Data Table on Japan - Year-over-year growth 2022-2027 (%) 9.12 Market opportunity by geography Exhibit 101: Market opportunity by geography ($ million) 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 102: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 103: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 104: Overview on factors of disruption 11.4 Industry risks Exhibit 105: Impact of key risks on business 12 Vendor Analysis 12.1 Vendors covered Exhibit 106: Vendors covered 12.2 Market positioning of vendors Exhibit 107: Matrix on vendor position and classification 12.3 AbbVie Inc. Exhibit 108: AbbVie Inc. - Overview Exhibit 109: AbbVie Inc. - Product / Service Exhibit 110: AbbVie Inc. - Key offerings 12.4 Bayer AG Exhibit 111: Bayer AG - Overview Exhibit 112: Bayer AG - Business segments Exhibit 113: Bayer AG - Key offerings Exhibit 114: Bayer AG - Segment focus 12.5 DKT International Exhibit 115: DKT International - Overview Exhibit 116: DKT International - Product / Service Exhibit 117: DKT International - Key offerings 12.6 EUROGINE SL Exhibit 118: EUROGINE SL - Overview Exhibit 119: EUROGINE SL - Product / Service Exhibit 120: EUROGINE SL - Key offerings 12.7 HLL Lifecare Ltd. Exhibit 121: HLL Lifecare Ltd. - Overview Exhibit 122: HLL Lifecare Ltd. - Product / Service Exhibit 123: HLL Lifecare Ltd. - Key offerings 12.8 Krishco Medical Products Pvt. Ltd. Exhibit 124: Krishco Medical Products Pvt. Ltd. - Overview Exhibit 125: Krishco Medical Products Pvt. Ltd. - Product / Service Exhibit 126: Krishco Medical Products Pvt. Ltd. - Key offerings 12.9 Laboratoire HRA Pharma SAS Exhibit 127: Laboratoire HRA Pharma SAS - Overview Exhibit 128: Laboratoire HRA Pharma SAS - Product / Service Exhibit 129: Laboratoire HRA Pharma SAS - Key offerings 12.10 Melbea Innovations Ltd. Exhibit 130: Melbea Innovations Ltd. - Overview Exhibit 131: Melbea Innovations Ltd. - Product / Service Exhibit 132: Melbea Innovations Ltd. - Key offerings 12.11 Ocon Medical Ltd. Exhibit 133: Ocon Medical Ltd. - Overview Exhibit 134: Ocon Medical Ltd. - Product / Service Exhibit 135: Ocon Medical Ltd. - Key offerings 12.12 Pregna International Ltd Exhibit 136: Pregna International Ltd - Overview Exhibit 137: Pregna International Ltd - Product / Service Exhibit 138: Pregna International Ltd - Key offerings 12.13 Prosan International BV Exhibit 139: Prosan International BV - Overview Exhibit 140: Prosan International BV - Product / Service Exhibit 141: Prosan International BV - Key offerings 12.14 SMB Corp. of India Exhibit: SMB Corp. of India - Overview Exhibit 142: SMB Corp. of India - Product / Service Exhibit 143: SMB Corp. of India - Key offerings 12.15 TESPRO LLC Exhibit 144: TESPRO LLC - Overview Exhibit 145: TESPRO LLC - Product / Service Exhibit 146: TESPRO LLC - Key offerings 12.16 The Cooper Companies Inc. Exhibit 147 : The Cooper Companies Inc. - Overview Exhibit 148: The Cooper Companies Inc. - Business segments Exhibit 149: The Cooper Companies Inc. - Key offerings Exhibit 150: The Cooper Companies Inc. - Segment focus 12.17 TRIMEDIC SUPPLY NETWORK Ltd. Exhibit 151: TRIMEDIC SUPPLY NETWORK Ltd. - Overview Exhibit 152: TRIMEDIC SUPPLY NETWORK Ltd. - Product / Service Exhibit 153: TRIMEDIC SUPPLY NETWORK Ltd. - Key offerings 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 154: Inclusions checklist Exhibit 155 : Exclusions checklist 13.3 Currency conversion rates for US$ Exhibit 157: Currency conversion rates for US$ 13.4 Research methodology Exhibit 158: Research methodology Exhibit 159: Validation techniques employed for market sizing Exhibit 160: Information sources 13.5 List of abbreviations Exhibit 161: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis